Please login to the form below

Paul Rice and Simon Walker join M3 (EU) as the company announces strong double-digit growth…

M3, the global healthcare technology company with brands including, medeConnect, M3 Global Research, Rotamaster and The Vidal Group has announced two significant appointments in Paul Rice who joins as Chief Operating Officer, and Simon Walker who takes on a Business Director role. This news comes as M3 Inc. releases its 2016 full-year results, with year-on-year revenue growing by 21%, and continued strong growth in key markets across Europe, US, Japan, China, Korea and India, and with membership of M3’s 100% verified physician communities now at over 4 million members.

Paul Rice has been appointed as Chief Operating Officer for M3’s rapidly expanding operations in Europe. Paul will lead the further development of M3’s services and the next phase of the company’s rapid growth in Europe. He brings more than 25 years of industry experience which includes senior roles at Merck and Walgreens Boots Alliance.Dr Tim Ringrose, CEO of M3 EU Ltd, commented “M3’s capabilities are becoming firmly established in key European markets and I’m delighted to welcome Paul to M3 as we continue to drive M3’s growth in key markets and expand the services we provide to healthcare”.

Simon Walker joins M3 (EU) as a Business Director, working across M3’s portfolio of promotional and medical education solutions in the UK and globally. Having initially trained as a journalist, Simon has had a successful career in medical publishing. After twenty years with BMJ (British Medical Journal), he set up a consultancy, TallSim Limited and has worked with organisations such as Kanga Healthcare and RCNi. He is also a committee member of Pharmaceutical Marketing Society.

About M3: M3 operates in Asia, the US and Europe with more than 4 million physician doctor members globally via, MDLinx, Medigate, M3 Medical and 5th on Forbes’ Most Innovative Growth Companies 2016, M3 provides pharmaceutical marketing, research services and career placement services for physicians.

For more information on the acquisition of Rotamaster by M3 please contact Hannah Brown on +44 (0)7747 273879 or For more information on M3 visit

30th May 2011


Company Details

M3 (EU)

+44 (0)1235 828400

Contact Website

101 Park Drive
Milton Park
Milton Park
OX14 4RY

Latest content on this profile

Learning to invest in doctors’ education
Pharmaceutical companies know doctors want high-value educational content. In a highly pressurised, cost-constrained healthcare environment with increasing demands for value and improved patient outcomes, time-poor doctors are calling out for more educational resources. However, the industry can find it hard to make a break from traditional methods of engaging with doctors, such as promotional communications and the traditional sales representative call to hospitals and GP surgeries.
M3 (EU)
Engaging doctors around the globe
Embedding a digital strategy as a prominent part of a pharmaceutical marketing campaign is becoming ever more important. Despite some perceived reluctance on the part of the industry, pharmaceutical companies are now exploring and exploiting a myriad of different digital channels in order to deliver content to, and engage with, their target audiences.
M3 (EU)
How do doctors spend their time online?
In our recent research piece, Doctor networks: The rules of engagement for pharma, some overarching principles for online engagement between the pharmaceutical industry and doctors were defined.
M3 (EU)
How do doctors want to engage with pharma on new products?
More than 80% of European doctors agree they are interested in staying up-to-date with new developments about pharmaceutical products. But what influences their choice of treatment and how do they prefer to receive product information?
M3 (EU)
M3 Acquires MirVracha LCC in Russia Launching Full-Scale Development of Physician Platform Business in Russia
M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; URL:; “M3” below) has announced the acquisition of MirVracha LCC (Headquarters: Moscow, Russia; CEO: Shotaro Yamamoto; “MirVracha” below), a website provider for healthcare professionals in Russia.   M3 operates, a specialized web portal for medical professionals that delivers healthcare related information to its 300,000+ physician members in Japan. Presence outside of Japan includes the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 6 million physicians as members across its global platforms.   This allows provision of services including marketing support, marketing research, and job placement support that leverage the platform’s powerful value as a media channel. MirVracha operates the medical professional website "МирВрача" with over 400,000 medical professional members, equivalent to roughly 60% of all physicians in Russia, and mainly provides marketing support services for pharmaceutical companies.   Since its founding by Shotaro Yamamoto in 2011, MirVracha has focused on building a quality network of healthcare professionals as well as improving content creation capabilities, and is now utilized by major Russian pharmaceutical companies to provide drug and disease information. In 2012, M3 entered into a capital and business alliance that includes the licensing of the MR-kun service, and have since developed a strong relationship with MirVracha through provision of support and know-how surrounding business launches and operations. M3 has completed the acquisition of MirVracha as a subsidiary, and will leverage its experience and know-how gained through its overseas business development in the United States, Europe, Asia, and other regions.   M3 will move forward with the full-scale development of services related to its physician platform in Russia by combining the high-quality network of physicians, medical institutions, and pharmaceutical companies that MirVracha has cultivated in Russia, with M3's expertise in operating websites and various services for healthcare professionals.
M3 (EU)
Revolutionising the Digital Content Delivery Model
Pharmaceutical industry processes don’t have to make the delivery of marketing campaigns slow and unmanageable, and thus ineffective. Changing working practices and really, truly thinking differently about how to deliver materials in a new and faster way is possible, but only if companies are ready to consider and embrace new, novel ways of working. Utilising these methods, M3 reduced a client's delivery time from 75 days to just 7.5 days
M3 (EU)